Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Kura Oncology
(NQ:
KURA
)
20.54
+0.36 (+1.78%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kura Oncology
< Previous
1
2
3
4
Next >
Earnings Preview: Kura Oncology
August 02, 2022
Kura Oncology (NASDAQ:KURA) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that Kura...
Via
Benzinga
Read Why Did Credit Suisse Raise Price Target On Kura Oncology
July 13, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2022
July 12, 2022
Upgrades
Via
Benzinga
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
August 18, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
August 17, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc...
Via
Benzinga
Kura Oncology Stock Scores Rising Relative Strength
June 30, 2022
On Thursday, Kura Oncology stock had its Relative Strength (RS) Rating stock upgraded to 93 from 81 a day earlier.
Via
Investor's Business Daily
PreMarket Prep: Looking For Biotech Bargains With This Wedbush Analyst
May 25, 2022
Biotechnology is one sector that peaked ahead of the S&P 500 index. While the S&P 500 index did not peak until January, the SPDR Biotech (NYSE: XBI) peaked in February 2021 and is now 60% lower than...
Via
Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
May 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
April 13, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal
Via
Benzinga
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
April 10, 2022
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion.
Via
Benzinga
Kura Oncology, Inc. (NASDAQ:KURA) Investor Notice: Investigation over Potential Wrongdoing
March 04, 2022
San Diego, CA -- (SBWIRE) -- 03/04/2022 -- Certain directors of Kura Oncology, Inc are under investigation over potential breaches of fiduciary duties.
Via
SBWire
Kura Oncology: Q4 Earnings Insights
February 24, 2022
Kura Oncology (NASDAQ:KURA) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 15, 2022
February 15, 2022
Upgrades For Blue Bird Corp (NASDAQ:BLBD), Roth Capital upgraded the previous rating of Neutral to Buy. Blue Bird earned $0.07 in the first quarter, compared to $0.00 in the year-...
Via
Benzinga
Groundbreaking Clinical Trials Accelerating New Treatment Options for Pancreatic Cancer
February 02, 2022
Palm Beach, FL – February 2, 2022 – FinancialNewsMedia.com News Commentary – In the battle against pancreatic cancer, new and innovative clinical trials have become extremely critical. These trials...
Via
FinancialNewsMedia
The Daily Biotech Pulse: Kura Lifts Clinical Hold On Blood Cancer Trial, Intuitive Surgical Earnings, Sorrento's Omicron Antibody Treatment Effective
January 21, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kura Announces Lifting Of Clinical Hold On Phase 1 Blood Cancer Study Kura...
Via
Benzinga
FDA Lifts Partial Hold On Kura Oncology's Early-Stage Leukemia Trial
January 21, 2022
The FDA has lifted the partial clinical hold on Kura Oncology Inc (NASDAQ: KURA) KOMET-001 Phase 1b study of KO-539 in patients with relapsed or refractory...
Via
Benzinga
NASDAQ:KURA Investor Notice: Investigation over Possible Securities Laws Violations by Kura Oncology, Inc.
December 09, 2021
San Diego, CA -- (SBWIRE) -- 12/09/2021 -- Kura Oncology, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Exposures
Product Safety
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
December 06, 2021
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...
Via
Benzinga
Exposures
Product Safety
68 Biggest Movers From Wednesday
November 26, 2021
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) shares gained 689.4% to settle at $78.94 on Wednesday after the company priced its IPO at $10 per share. Longeveron Inc. (...
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
40 Stocks Moving In Wednesday's Mid-Day Session
November 24, 2021
Gainers Biofrontera Inc. (NASDAQ: BFRI) shares jumped 109.5% to $5.51 after Roth Capital initiated coverage on the stock with a Buy rating and a $20 price target. Longeveron Inc...
Via
Benzinga
Why Kura Oncology Stock Is Sliding Today
November 24, 2021
A partial clinical hold for the company's experimental leukemia treatment is making investors nervous.
Via
The Motley Fool
See Why FDA Hit Red Light On Kura's Early-Stage Leukemia Trial
November 24, 2021
The FDA has slapped a partial clinical hold on the early-stage program for one of Kura Oncology Inc’s (NASDAQ: KURA) cancer drugs following a patient...
Via
Benzinga
Exposures
Product Safety
FDA Slams Kura Oncology With A Clinical Hold — And Investors Slam Its Stock
November 24, 2021
Kura can continue to treat patients, but it can't enroll new patients in its study.
Via
Investor's Business Daily
Topics
Death
Exposures
Death
Product Safety
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 24, 2021
Gainers Ocuphire Pharma (NASDAQ:OCUP) stock rose 78.73% to $6.22 during Wednesday's pre-market session. The market value of their outstanding shares is at $107.6...
Via
Benzinga
The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension
November 24, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Puma Biotech Announces Receipt Of Patent Extension For Breast Cancer Drug By...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Kura Oncology, inc (KURA) Q3 2021 Earnings Call Transcript
November 05, 2021
KURA earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
November 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...
Via
Benzinga
Exposures
COVID-19
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
Jon Najarian Sees Unusual Options Activity In Lucid Motors, Kura Oncology And More
August 24, 2021
Jon Najarian spoke on CNBC's "Options Action" about unusually high options activity in Lucid Group Inc (NASDAQ: LCID) on Tuesday. He said options traders are buying...
Via
Benzinga
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
August 20, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS...
Via
Benzinga
Exposures
COVID-19
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.